Psycheceutical Bioscience, Inc (OTCPK: BWVI) is conducting trials in Australia for its NeuroDirect system, a topical drug delivery method that can deliver psychedelic drugs directly to the brain. The company recently completed dosing the first cohort of subjects in a Phase I clinical trial of its topical ketamine formulation for PTSD. The NeuroDirect system could have applications for a wide range of neuro-related conditions. The patents for NeuroDirect are owned by DEF, LLC and four of them have been licensed to Psycheceutical.